PMCB ABANDONS MILLIONS IN PROJECTS INCLUDING TATTOO INK, CINNSATIONAL DRINK, and many many more. After spending MILLIONS ON LOST PROJECTS COMPANY SIDE STEPS TO LAPC COMMUNITY BEATING A DEAD HORSE OF SCIENCE ALREADY ADVANCED BY A MYRIAD OF COMPANIES ALREADY USING CELL ENCAPSULATION. Look it up!!! Go type in cellulose cell encapsulation, diabetes cell encapsulation into google and actually read the studies not associated with PMCB. They have NO PATENT ON SOMETHING THEY PAID MILLIONS FOR FROM A FOREIGN COMPANY! We have more transactions of the AUSTRIA NOVA acquisition than I can count at the moment. They continually flip the script in the amount of ownership the type of ownership and the products licensed including their abandonment of the diabetes program WITHOUT mentioning it to investors. They have no intention of pursuing Diabetes treatment. They are much much too late and WAYYYYYY BEHIND THE CURVE HERE. Look it Uppppp!!!! Their financials tell a COMPLETELY DIFFERENT STORY WHICH IS WHY THEY HAVE BEEN AUDITED BY SEO and received CEASE TRADE ORDER by BCSC
PMCB was a nutraceutical license company for 15+ years before becoming a Biotech licensing company who does ZERO of the science, medicine or development. They rely on investors to supply them with free money to pay their EXORBITANT SALARIES, and pay for the licenses so they can produce ZERO RETURN for investors.
CEO IS DEFENDANT TO FRAUD IN 2 SEPARATE CASES IN HIS HOME TOWN.
CEO files amended filing after late filing after amended filing to SEO all while collecting over 670,000 a year for doing nothing but spin words around like the terrible attorney he is. The CEO couldn’t even keep his car registration current. Right there in his criminal background check.
Don’t forget when Kenny said this in 2016:
“Last Monday I tried to address certain issues that shareholders and potential investors have raised repeatedly about our upcoming clinical trial and provide an update on our efforts to complete the process of preparing the Investigational New Drug application (IND) that PharmaCyte must submit to the FDA to start our clinical trial in pancreatic cancer. Given the number of telephone calls and emails the Company has received since that update was published, it has become apparent that the update caused confusion and raised issues of concern that were never intended.
“When it was stated on Monday that the expected ‘start date’ for PharmaCyte’s clinical trial in pancreatic cancer remains difficult to announce with certainty, we were not implying that we aren’t still on schedule to get into the clinic in 2016 or that we don’t have any idea when we will be in the clinic. We plan to be in the clinic well before the end of this year. It was simply a statement that intended to refrain from announcing a specific date or time period for starting the trial because much of what is left to complete is out of our control.
This will happen AGAIN. IN FACT IT ALREADY HAS WHEN HE CLAIMS WE ARE ENGAGING FDA. We don’t engage FDA. They engage us. It’s a tricky play on words but makes it seem like we are the ones writing the script. FDA WILL HOLD THIS NO DOUBT!
